You are here

Market Exclusivity Conferred for Tramadol ER by FDA

TORONTO--(BUSINESS WIRE)--Oct. 21, 2005--Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that the United States Food and Drug Administration (FDA) has confirmed - and has posted on its Orange Book Web site - that Biovail's once-daily extended-release formulation of tramadol (Tramadol ER) has received three years of exclusivity, covering all dosages.

"Being the first-to-market with a once-daily formulation of tramadol is a significant competitive advantage," said Biovail Chief Executive Officer Dr. Douglas Squires. "The additional benefit of three years of market exclusivity only enhances the value of Tramadol ER."

Source: Biovail Corporation

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs